Müge Pınar Çakar ÖZDAL, Merve İnanç TEKİN

Ophthalmic Manifestations of ANCA-Associated Vasculitis

Ocular manifestations in antineutrophil cytoplasmic antibodyassociated vasculitis can be associated with the general or limited form of disease and can even occur in the absence of systemic disease. Ocular manifestations of associated vasculitis can be the first symptom of previously not manifested or undiagnosed systemic disease, allowing ophthalmologists to contribute to the diagnosis. Although its ocular findings are variable and nonspecific, the presence of necrotizing changes and peripheral corneal involvement accompanying scleral inflammation are important clues suggesting systemic vasculitis, especially associated vasculitis. The disease may affect all layers of the eye; scleritis and orbital involvement being the most common. Conjunctivitis, episcleritis, peripheral ulcerative keratitis, uveitis and retinal vasculitis are other ocular findings that may be observed during the disease course. Ocular involvement is most commonly seen in granulomatosis with polyangiitis followed by eosinophilic granulomatosis with polyangiitis and microscopic polyangiitis. Due to the high morbidity and mortality of associated vasculitis, it is very important to recognize the ocular manifestations of vasculitis as a sign of the underlying systemic disease and an indicator for the disease activity. Treatment varies depending on the location and severity of the ocular involvement. Although localized medical and surgical treatments can help to manage associated ocular disease, systemic immunosuppressive medications are often required to control the underlying disease. With the increasing availability and use of biological agents, prognosis has improved in patients with severe ocular complications. Rituximab appears to be useful in inducing remission and controlling relapses in patients with ocular involvement of associated vasculitis, particularly in cyclophosphamide resistant cases. A multidisciplinary approach in the diagnosis, treatment and follow-up of patients with associated vasculitis is required in order to achieve successful results.

PDF

___

[1] Pagnoux C. Updates in ANCA-associated vasculitis. Eur J Rheumatol 2016; 3(3): 122-133.
[2] Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 2013; 65(1): 1-11.
[3] Leavitt RY, Fauci AS, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of Wegener’s granulomatosis. Arthritis Rheum 1990; 33(8): 1101-1107.
[4] Masi AT, Hunder GG, Lie JT, et al. The American College of Rheumatology 1990 criteria for the classification of Churg- Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum 1990; 33(8): 1094-1100.
[5] Rothschild PR, Pagnoux C, Seror R, et al. Ophthalmologic manifestations of systemic necrotizing vasculitides at diagnosis: a retrospective study of 1286 patients and review of the literature. Semin Arthritis Rheum. 2013; 42(5): 507-514.
[6] Miyanaga M, Takase H, Ohno-Matsui K. Anti-Neutrophil Cytoplasmic Antibody-Associated Ocular Manifestations in Japan: A Review of 18 Patients. Ocul Immunol Inflamm. 2020;1-6.
[7] Ungprasert P, Crowson CS, Cartin-Ceba R, et al. Clinical characteristics of inflammatory ocular disease in antineutrophil cytoplasmic antibody associated vasculitis: a retrospective cohort study. Rheumatology (Oxford) 2017; 56(10): 1763-1770.
[8] Watkins AS, Kempen JH, Dongseok C, et al. Ocular disease in patients with ANCA-positive vasculitis. J Ocul Biol Dis Infor. 2009; 3(1): 12-19.
[9] Pulido JS, Goeken JA, Nerad JA, et al. Ocular manifestations of patients with circulating antineutrophil cytoplasmic antibodies. Arch Ophthalmol 1990; 108: 845-850.
[10] Caster JC, Shetlar DJ, Pappolla MA, et al. Microscopic polyangiitis with ocular involvement. Arch Ophthalmol 1996; 114: 346-348.
[11] Tarabishy AB, Schulte M, Papaliodis GN, et al. Wegener’s granulomatosis: clinical manifestations, differential diagnosis, and management of ocular and systemic disease. Surv Ophthalmol 2010; 55 (5): 429-444.
[12] Perez VL, Chavala SH, Ahmed M, et al. Ocular manifestations and concepts of systemic vasculitides. Surv Ophthalmol 2004; 49(4): 399-418.
[13] Robinson MR, Lee SS, Sneller MC, et al. Tarsal-conjunctival disease associated with Wegener’s granulomatosis. Ophthalmology. 2003; 110: 1770-1780.
[14] Fortney AC, Chodosh J. Conjunctival ulceration in recurrent Wegener granulomatosis. Cornea. 2002; 21(6): 623-624. [15] Meier F, Messmer E, Bernauer W. Wegener’s granulomatosis as a cause of cicatrising conjunctivitis. Br J Ophthalmol. 2001; 85(5): 625.
[16] Jordan DR, Zafar A, Brownstein S, et al. Cicatricial conjunctival inflammation with trichiasis as the presenting feature of Wegener granulomatosis. Ophthal Plast Reconstr Surg. 2006; 22: 69-71.
[17] Gu J, Zhou S, Ding R, et al. Necrotizing Scleritis and Peripheral Ulcerative Keratitis Associated with Wegener’s Granulomatosis. Ophthalmol Ther. 2013; 2(2): 99-111.
[18] Akpek EK, Uy HS, Christen W, et al. Severity of episcleritis and systemic disease association. Ophthalmology. 1999; 106(4): 729-731.
[19] Sainz de la Maza M, Foster CS, Jabbur NS. Scleritis associated with systemic vasculitic diseases. Ophthalmology 1995; 102: 687-692.
[20] Watson PG, Hayreh SS. Scleritis and episcleritis. Br J Ophthalmol 1976; 60(3): 163-191.
[21] Jabs DA, Mudun A, Dunn JP, et al. Episcleritis and scleritis: clinical features and treatment results. Am J Ophthalmol 2000; 130(4): 469-476.
[22] Cocho L, Gonzalez-Gonzalez LA, Molina-Prat N, et al. Scleritis in patients with & granulomatosis with polyangiitis (Wegener). Br J Ophthalmol 2016; 100: 1062-1065.
[23] Bernauer W, Pleisch B, Brunner M. Five-year outcome in immune-mediated scleritis. Graefes Arch Clin Exp Ophthalmol 2014; 252: 1477-1481.
[24] Hoang LT, Lim LL, Vaillant B, et al. Antineutrophil cytoplasmic antibody-associated active scleritis. Arch Ophthalmol. 2008; 126(5): 651-655.
[25] Rosenbaum JT. The eye and rheumatic diseases. In: Firestein GS, Budd RC, Gabriel SE, McInnes IB, O’Dell JR (eds) Kelley and Firestein’s textbook of rheumatology. Philadelphia, Elsevier, 2017 pp 645-653 (Chapter 44).
[26] Wieringa WG, Wieringa JE, ten Dam-van Loon NH, et al. Visual outcome, treatment results, and prognostic factors in patients with scleritis. Ophthalmology. 2013; 120: 379- 386.
[27] Foster CS, Forstot SL, Wilson LA. Mortality rate in rheumatoid arthritis patients developing necrotizing scleritis or peripheral ulcerative keratitis. Effects of systemic immunosuppression. Ophthalmology 1984; 91(10): 1253-1256.
[28] Messmer EM, Foster CS. Vasculitic peripheral ulcerative keratitis. Surv Ophthalmol 1999; 43: 379-396.
[29] García C, Voorduin S, Pedroza-Seres M. Diagnosis of Wegener’s granulomatosis in patients with ocular inflamatory disease. Gac Med Mex 2006; 142(6): 477-482.
[30] Smith VA, Hoh HB, Easty DL. Role of ocular metalloproteinases in peripheral ulcerative keratitis. Br J Ophthalmol 1999; 83: 1376-1383.
[31] Sainz de la Maza M, Foster CS, Jabbur NS, et al. Ocular characteristics and disease associations in scleritisassociated peripheral keratopathy. Arch Ophthalmol 2002; 120: 15-19.
[32] Tauber J, Sainz de la Maza M, Hoang-Xuan T, et al. An analysis of therapeutic decision making regarding immunosuppressive chemotherapy for peripheral ulcerative keratitis. Cornea 1990; 9(1): 66-73.
[33] Ebrahimiadib N, Modjtahedi BS, Roohipoor R, et al. Successful Treatment Strategies in Granulomatosis with Polyangiitis-Associated Peripheral Ulcerative Keratitis. Cornea. 2016; 35(11): 1459-1465.
[34] Spalton DJ, Graham EM, Page NG, et al. Ocular changes in limited forms of Wegener’s granulomatosis. Br J Ophthalmol 1981; 65(8): 553-563.
[35] Cassan SM, Coles DT, Harrison EG Jr. The concept of limited forms of Wegener’s granulomatosis. Am J Med 1970; 49: 366-379.
[36] du Huong LT, Tran TH, Piette JC. Granulomatous uveitis revealing Wegener’s granulomatosis. J Rheumatol 2006; 33: 1209-1210.
[37] Gheita TA, Abd El Latif EM. Relationship of ocular presentation in granulomatosis with polyangiitis to autoantibodies and disease activity. Z Rheumatol. 2019; 78(3): 281-286.
[38] Harman LE, Margo CE. Wegener’s granulomatosis. Surv Ophthalmol 1998; 42: 458-480.
[39] Bullen CL, Liesegang TJ, McDonald TJ, et al. Ocular complications of Wegener’s granulomatosis. Ophthalmology 1983; 90 (3): 279-290.
[40] Lin M, Anesi SD, Ma L, et al. Characteristics and Visual Outcome of Refractory Retinal Vasculitis Associated with Antineutrophil Cytoplasm Antibody-Associated Vasculitides. Am J Ophthalmol. 2018; 187: 21-33.
[41] Venkatesh P, Chawla R, Tewari HK. Hemiretinal vein occlusion in Wegener’s granulomatosis. Eur J Ophthalmol 2003; 13: 722-725.
[42] Wang M, Khurana RN, Sadda SR. Central retinal vein occlusion in Wegener’s granulomatosis without retinal vasculitis. Br J Ophthalmol. 2006; 90(11): 1435-1436.
[43] Kubaisi B, Abu Samra K, Foster CS. Granulomatosis with polyangiitis (Wegener’s disease): An updated review of ocular disease manifestations. Intractable Rare Dis Res. 2016; 5(2): 61-69.
[44] McNab AA. The 2017 Doyne Lecture: the orbit as a window to systemic disease. Eye (Lond). 2018; 32(2): 248-261.
[45] Jiang B, Zhao YY, Wei SH. Granulomatosis with polyangiitis: the relationship between ocular and nasal disease. Ocul Immunol Inflamm. 2013; 21(2): 115-118.
[46] Holle JU, Voigt C, Both M, et al. Orbital masses in granulomatosis with polyangiitis are associated with a refractory course and a high burden of local damage. Rheumatology (Oxford) 2013; 52(5): 875-882.
[47] Hoffman GS, Kerr GS, Leavitt RY et al. Wegener‘s granulomatosis: an analysis of 158 patients. Ann Intern Med. 1992; 116(6): 488-498.
[48] Jinnah HA, Dixon A, Brat DJ, et al. Review chronic meningitis with cranial neuropathies in Wegener’s granulomatosis. Case report and review of the literature. Arthritis Rheum 1997; 40(3): 573-577.
[49] Chung S, Monach PA. Anti-neutrophil cutoplasmic antibody-associated vasculitis. In: Firestein GS, Budd RC, Gabriel SE, McInnes IB, O’Dell JR (eds) Kelley and Firestein’s textbook of rheumatology. Philadelphia, Elsevier, 2017, pp 1541-1558 (Chapter 89)
[50] Woo TL, Francis IC, Wilcsek GA et al. Australasian orbital and adnexal Wegener‘s granulomatosis. Ophthalmology 2001;108(9);1535-1543.
[51] Ismailova DS, Abramova JV, Novikov PI, et al. Clinical features of different orbital manifestations of granulomatosis with polyangiitis. Graefes Arch Clin Exp Ophthalmol. 2018;256(9):1751-1756.
[52] Fauci AS, Wolff SM, Johnson JS. Effect of cyclophosphamide upon the immune response in Wegener’s granulomatosis. N Engl J Med 1971; 285 (27):1493-1496.
[53] Novack SN, Pearson CM. Cyclophosphamide therapy in Wegener’s granulomatosis. N Engl J Med 1971; 284 (17):938-942.
[54] Stone JH, Merkel PA, Spiera R, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010; 363 (3):221-232
[55] Jones RB, Tervaert JW, Haus er T, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 2010; 363 (3):211-220.
[56] Huerva V, Sanchez MC, Traveset A, et al. Rituximab for peripheral ulcerative keratitis with wegener granulomatosis. Cornea 2010; 29 (6):708-710.
[57] You C, Ma L, Lasave AF, et al. Rituximab Induction and Maintenance Treatment in Patients with Scleritis and Granulomatosis with Polyangiitis (Wegener’s). Ocul Immunol Inflamm 2018; 26(8):1166-1173.
[58] Seo P, Specks U, Keogh KA. Efficacy of rituximab in limited Wegener’s granulomatosis with refractory granulomatous manifestations. J Rheumatol 2008; 35:(10):2017-2023.
[59] Ahmed A, Foster CS. Cyclophosphamide or Rituximab Treatment of Scleritis and Uveitis for Patients with Granulomatosis with Polyangiitis. Ophthalmic Res. 2019; 61(1):44-50.